FTSE 100 today: Index flat at open, European markets mixed; pound weakens
LONDON - ANGLE plc (AIM:AGL OTCQX:ANPCY), a liquid biopsy company focused on circulating tumor cell diagnostic solutions, will publish its interim results for the six months ended June 30, 2025, on Tuesday, September 9.
The company will host a virtual analyst meeting at 11:00 am BST on the same day. The decision to hold the meeting virtually comes in response to planned tube strikes in London.
A live webcast of the analyst meeting will be available through ANGLE’s website, with question and answer participation limited to analysts. The company plans to make a recording of the webcast available following the meeting.
ANGLE describes itself as providing circulating tumor cell solutions for research, drug development, and clinical oncology applications using blood samples. The company’s FDA-cleared Parsortix PC1 System is designed to harvest circulating tumor cells for downstream analysis.
The company’s business focuses on clinical services through its laboratories and diagnostic products including the Parsortix system and related consumables and assays.
This information is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.